OOIR: Observatory of International Research

Papers

(The TQCC of Oncoimmunology is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors	105
Loss of the extracellular protease ADAMTS1 reveals an antitumorigenic program involving the action of NIDOGEN-1 on macrophage polarization	103
Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials	82
The endoplasmic reticulum chaperone BiP: a target for immunogenic cell death inducers?	72
T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction	71
Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status	68
MicroRNA analysis of Natural Killer cell-derived exosomes: the microRNA let-7b-5p is enriched in exosomes and participates in their anti-tumor effects against pancreatic cancer cells	67
Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition	64
Targeting 3D chromosomal architecture at the RANK loci to suppress myeloma-driven osteoclastogenesis	62
Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection	61
Ferroptosis: friend or foe in cancer immunotherapy?	60
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors	60
Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer	57
Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer	51
STING is significantly increased in high-grade glioma with high risk of recurrence	51
PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis	46
The anti-inflammatory cytokine IL-37 improves the NK cell-mediated anti-tumor response	44
Correction	44
Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas	43
IRE1α overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response	42
CPT1C-positive cancer-associated fibroblast facilitates immunosuppression through promoting IL-6-induced M2-like phenotype of macrophage	42
Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition	42
Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response	41
Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates	41
CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival	40

A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC	40
Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8 ⁺ T cells eradicates peritoneal metastases in mouse models	39
Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence	39
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma	39
PD-1 is expressed in cytotoxic granules of NK cells and rapidly mobilized to the cell membrane following recognition of tumor cells	38
Enhancement of tumor immunogenicity by the introduction of non- proteinogenic amino acid azetidine-2-carboxylic acid	36
Reprogramming monocyte-derived macrophages through caspase inhibition	36
Targeting the activin receptor 1C on CD4+ T cells for cancer immunotherapy	35
CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model	35
Improving STING agonist-based cancer therapy by inhibiting the autophagy-related protein VPS34	35
Lactate/GPR81 recruits regulatory T cells by modulating CX3CL1 to promote immune resistance in a highly glycolytic gastric cancer	35
Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab	34
Markers of tumor-associated macrophages and microglia exhibit high intratumoral heterogeneity in human glioblastoma tissue	32
Immune sunrise: from the immunome to the cancer immune landscape	32
Synergistic effect of combining sunitinib with a peptide-based vaccine in cancer treatment after microenvironment remodeling	31
Immunogenic stress induced by local anesthetics injected into neoplastic lesions	31
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases	31
Accumulation of tissue-resident natural killer cells, innate lymphoid cells, and CD8 ⁺ T cells towards the center of human lung tumors	31
Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy	31
Interferon regulatory factor 4 plays a pivotal role in the development of aGVHD-associated colitis	31
Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer	31
Liver metastases of colorectal cancer contain different subsets of tissue-resident memory CD8 T cells correlated with a distinct risk of relapse following surgery	31
Neoadjuvant immune checkpoint blockade triggers persistent and systemic T _reg activation which blunts therapeutic efficacy against metastatic spread of breast tumors	31
Cell therapy for a rare disease- hairy cell leukemia variant	30
Tumor-infiltrating B cells produce tumor-specific antibodies and may contribute to suppressing tumor in head and neck squamous cell carcinoma	30
TNFR2/CCR8 bispecific antibody enhances antitumor activity through depleting Ti-Tregs and boosting effector CD8 ⁺ T cell function	29
Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy	29
Phenotypic characterization of spatial immune infiltration niches in non-small cell lung cancer	29
Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade	29
Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation	29
Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML	29
A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination	28
Trial watch: beta-blockers in cancer therapy	27
SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion	27
Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors	27
Spermidine rejuvenates T lymphocytes and restores anticancer immunosurveillance in aged mice	26
The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology	26
Candidate tumor-specific CD8 ⁺ T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis	26
A diversity outbred F1 mouse model identifies host-intrinsic genetic regulators of response to immune checkpoint inhibitors	26
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)	26
Targeting coagulation to unlock antitumor immunity?	25
Surrogate markers of intestinal dysfunction associated with survival in advanced cancers	25
M2 macrophage-derived exosomes suppress tumor intrinsic immunogenicity to confer immunotherapy resistance	25
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response	24
Schweinfurthin induces ICD without ER stress and caspase activation	24
Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors	24
MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4 ⁺ T cells in vivo	23
Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes	23
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response	23
Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancer	23

Mitochondrial DNA transfer between malignant cells and T lymphocytes shapes the cancer-immunity dialogue	23
Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products	23
CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies	23
Interleukin-27 tackles immunosuppression in chronic lymphocytic leukemia	23
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy	23
CD8 ⁺ T cells in breast cancer tumors and draining lymph nodes: PD-1 levels, effector functions and prognostic relevance	22
Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma	22
Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)	22
Gasdermin E links tumor cell-intrinsic nucleic acid signaling to proinflammatory cell death for successful checkpoint inhibitor cancer immunotherapy	22
A novel membrane-bound interleukin-2 promotes NK-92 cell persistence and anti-tumor activity	22
Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc)	22
Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer	22
Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade	22
Cell type-specific induction of ferroptosis to boost antitumor immunity	21
Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma	21
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression	21
Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis	21
IL-21-reprogrammed Vδ1 T cells exert killing against solid tumors which is enhanced by CAR arming for off-the-shelf immunotherapy	20
Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer	20
Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction	20
Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting	20
Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression	20
High-grade serous ovarian cancer development and anti-PD-1 resistance is driven by IRE1α activity in neutrophils	20
BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and γδ T-cells that can be further expanded in vitro	20
Piezo1 facilitates optimal T cell activation during tumor challenge	20
Metabolic heterogeneity in tumor cells impacts immunology in lung squamous cell carcinoma	20
Enriched circulating and tumor-resident TGF-β ⁺ regulatory B cells in patients with melanoma promote FOXP3 ⁺ Tregs	19
Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome	19
g-NK cells from umbilical cord blood are phenotypically and functionally different than g-NK cells from peripheral blood	19
Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy	19
Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors	19
Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition	19
Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-γ/IL-17 release in bladder cancer treatment	19
Activation of endogenous glucocorticoids by HSD11B1 inhibits the antitumor immune response in renal cancer	19
Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies	19
LCVM infection generates tumor antigen-specific immunity and inhibits growth of nonviral tumors	19
The long-lasting expression of recombinant artLCMV following intraperitoneal administration exerts potent antitumor effects on tumor models of peritoneal carcinomatosis	19
Regional immune mechanisms enhance efficacy of an autologous cellular cancer vaccine with intraperitoneal administration	18
Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden	18
Small extracellular vesicles: multi-faceted tools for leukemia immune evasion in vivo	18
Non-pharmaceutical interventions to optimize cancer immunotherapy	17
Arsenic trioxide as an inducer of immunogenic cell death	17
Single-cell analysis of T lymphocytes infiltrating colorectal carcinoma: the dilemma of specificity	17
Cytoplasmic HMGB2 orchestrates CALR translocation in the course of immunogenic cell death	16
CD4 ⁺ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts	16
Extracellular vesicles released by cancer-associated fibroblast-induced myeloid-derived suppressor cells inhibit T-cell function	16
Systemic administration of a viral nanoparticle neoadjuvant prevents lung metastasis development through emergency myelopoiesis	16
Tumor-associated macrophages promote intratumoral conversion of conventional CD4 ⁺ T cells into regulatory T cells via PD-1 signalling	16
Are tumor-associated carbohydrates the missing link between the gut microbiome and response to immune checkpoint inhibitor treatment in cancer?	16
How macrophages use extracellular calreticulin to chase their prey	16
Human allogenic γδ T cells kill patient-derived glioblastoma cells expressing high levels of DNAM-1 ligands	16
CD4+ T cell-derived IL-22 enhances liver metastasis by promoting angiogenesis	15
EphA2 and phosphoantigen-mediated selective killing of medulloblastoma by γδT cells preserves neuronal and stem cell integrity	15
Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors	15
Cross-disease integration of single-cell RNA sequencing data from lung myeloid cells reveals TAM signature in in vitro model	15
Salmonella immunotherapy engineered with highly efficient tumor antigen coating establishes antigen-specific CD8+ T cell immunity and increases in antitumor efficacy with type I int	15
QPCTL regulates macrophage and monocyte abundance and inflammatory signatures in the tumor microenvironment	15
Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor	15
Near-infrared duocarmycin photorelease from a Treg-targeted antibody-drug conjugate improves efficacy of PD-1 blockade in syngeneic murine tumor models	15
Metabolic regulation of the mitochondrial immune checkpoint	15
Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses	15
Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases	15
Acquired DNA damage repairs deficiency-driven immune evolution and involved immune factors of local versus distant metastases in non-small cell lung cancer	15
Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival	15